Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Suspected interstitial lung disease on chest imaging can closely resemble infectious conditions like pneumonia. Involving pulmonary specialists early for inpatient evaluation, viral testing, or bronchoscopy prevents physicians from unnecessarily stopping effective trastuzumab deruxtecan therapy for a misdiagnosed toxicity, while ensuring true pulmonary complications receive rapid steroid or antibiotic intervention.

Related Insights

For urothelial cancer patients treated with trastuzumab deruxtecan (TDXD), developing symptomatic (Grade 2) interstitial lung disease or pneumonitis is a critical event. Following protocols from other cancers, this requires permanent discontinuation of the therapy. Re-challenging the patient with TDXD after a Grade 2 event is not recommended without more disease-specific safety data.

The discovery of low-grade, asymptomatic interstitial lung disease (ILD) on scans for patients on certain ADCs does not mandate permanent discontinuation. By holding the drug, initiating steroids, and involving pulmonology, the inflammation can resolve, often allowing the patient to safely resume a highly effective therapy.

With ADCs carrying a risk of interstitial lung disease (ILD), a critical safety measure is to act on radiological findings alone. Even if a patient is completely asymptomatic, new ground-glass opacities on a CT scan require an immediate treatment hold to prevent potentially rapid and severe pneumonitis.

For patients with lung metastases and symptoms like shortness of breath, choosing an ADC becomes complex. The primary concern is the inability to distinguish between disease progression and drug-induced interstitial lung disease (ILD), a known risk with certain ADCs. This diagnostic ambiguity can lead clinicians to favor ADCs with a lower ILD risk profile.

Unlike pneumonitis from immune checkpoint inhibitors, which responds quickly to steroids, pneumonitis from ADCs like trastuzumab deruxtecan is less responsive and slower to resolve. This critical difference requires a lower threshold for holding therapy and more cautious management to avoid permanent lung damage.

Given the risk of interstitial lung disease (ILD) with TDXD, clinicians should consider a baseline pulmonology consult for NSCLC patients with pre-existing lung issues. This proactive step helps establish a baseline and can prevent mismanaging potential adverse events.

The management of treatment-induced pneumonitis differs significantly between drug classes. While clinicians may treat through low-grade pneumonitis from immune checkpoint inhibitors, the safest approach for antibody-drug conjugates (ADCs) like TDXD is to stop the drug immediately upon any radiographic evidence, even if the patient is asymptomatic.

Unlike some immunotherapy guidelines, experts recommend immediate steroid treatment for even Grade 1 (asymptomatic) ADC-induced pneumonitis or interstitial lung disease (ILD) found on scans. This aggressive, proactive approach is considered necessary due to the risk of rapid clinical deterioration, prioritizing safety and the ability to resume cancer therapy.

Interstitial lung disease (ILD) is a serious risk with trastuzumab deruxtecan (TDXD). Oncologists must take it extremely seriously, engaging a pulmonologist immediately at the first sign of symptoms or CT scan findings. A collaborative, multidisciplinary approach is essential for safely managing this potentially fatal toxicity.

To proactively screen for interstitial lung disease (ILD), a serious risk with trastuzumab deruxtecan (TDXD), imaging should be conducted more frequently than the typical 12-week interval. The recommended strategy is to scan patients every nine weeks, or after every three cycles, to identify asymptomatic Grade 1 ILD cases early.